Cargando…
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and...
Autores principales: | Quagliariello, Vincenzo, Passariello, Margherita, Di Mauro, Annabella, Cipullo, Ciro, Paccone, Andrea, Barbieri, Antonio, Palma, Giuseppe, Luciano, Antonio, Buccolo, Simona, Bisceglia, Irma, Canale, Maria Laura, Gallucci, Giuseppina, Inno, Alessandro, De Lorenzo, Claudia, Maurea, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505026/ https://www.ncbi.nlm.nih.gov/pubmed/36158826 http://dx.doi.org/10.3389/fcvm.2022.930797 |
Ejemplares similares
-
Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
por: Quagliariello, Vincenzo, et al.
Publicado: (2023) -
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
por: Quagliariello, Vincenzo, et al.
Publicado: (2023) -
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
por: Quagliariello, Vincenzo, et al.
Publicado: (2021) -
EDA-Containing Fibronectin Increases Proliferation of Embryonic Stem Cells
por: Losino, Noelia, et al.
Publicado: (2013) -
Keloid Pathogenesis: Potential Role of Cellular Fibronectin with the EDA Domain
por: Andrews, Jonathan P., et al.
Publicado: (2015)